367 related articles for article (PubMed ID: 27900363)
1. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
[TBL] [Abstract][Full Text] [Related]
2. Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management.
Gupta S; Vanderbilt CM; Cotzia P; Arias-Stella JA; Chang JC; Zehir A; Benayed R; Nafa K; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME; Ross DS
J Mol Diagn; 2019 Mar; 21(2):307-317. PubMed ID: 30576871
[TBL] [Abstract][Full Text] [Related]
3. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Budczies J; Denkert C; Győrffy B; Schirmacher P; Stenzinger A
BMC Med Genomics; 2017 Dec; 10(1):74. PubMed ID: 29212506
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
Gatalica Z; Xiu J; Swensen J; Vranic S
Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
[TBL] [Abstract][Full Text] [Related]
6. Molecular driver alterations and their clinical relevance in cancer of unknown primary site.
Löffler H; Pfarr N; Kriegsmann M; Endris V; Hielscher T; Lohneis P; Folprecht G; Stenzinger A; Dietel M; Weichert W; Krämer A
Oncotarget; 2016 Jul; 7(28):44322-44329. PubMed ID: 27322425
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary.
Wang X; Beharry A; Sheffield BS; Cheema PK
Oncologist; 2023 Jun; 28(6):474-478. PubMed ID: 36933203
[TBL] [Abstract][Full Text] [Related]
8. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
Balko JM; Schwarz LJ; Luo N; Estrada MV; Giltnane JM; Dávila-González D; Wang K; Sánchez V; Dean PT; Combs SE; Hicks D; Pinto JA; Landis MD; Doimi FD; Yelensky R; Miller VA; Stephens PJ; Rimm DL; Gómez H; Chang JC; Sanders ME; Cook RS; Arteaga CL
Sci Transl Med; 2016 Apr; 8(334):334ra53. PubMed ID: 27075627
[TBL] [Abstract][Full Text] [Related]
10. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
[TBL] [Abstract][Full Text] [Related]
11. Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.
Van Roosbroeck K; Ferreiro JF; Tousseyn T; van der Krogt JA; Michaux L; Pienkowska-Grela B; Theate I; De Paepe P; Dierickx D; Doyen C; Put N; Cools J; Vandenberghe P; Wlodarska I
Genes Chromosomes Cancer; 2016 May; 55(5):428-41. PubMed ID: 26850007
[TBL] [Abstract][Full Text] [Related]
12. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification.
Chen M; Andreozzi M; Pockaj B; Barrett MT; Ocal IT; McCullough AE; Linnaus ME; Chang JM; Yearley JH; Annamalai L; Anderson KS
Mod Pathol; 2017 Nov; 30(11):1516-1526. PubMed ID: 28752839
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy induces enrichment of CD47
Samanta D; Park Y; Ni X; Li H; Zahnow CA; Gabrielson E; Pan F; Semenza GL
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1239-E1248. PubMed ID: 29367423
[TBL] [Abstract][Full Text] [Related]
15. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.
Barrett MT; Anderson KS; Lenkiewicz E; Andreozzi M; Cunliffe HE; Klassen CL; Dueck AC; McCullough AE; Reddy SK; Ramanathan RK; Northfelt DW; Pockaj BA
Oncotarget; 2015 Sep; 6(28):26483-93. PubMed ID: 26317899
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
[TBL] [Abstract][Full Text] [Related]
17. Cancer of Unknown Primary in the Molecular Era.
Kato S; Alsafar A; Walavalkar V; Hainsworth J; Kurzrock R
Trends Cancer; 2021 May; 7(5):465-477. PubMed ID: 33516660
[TBL] [Abstract][Full Text] [Related]
18. Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer.
Nakayama Y; Mimura K; Tamaki T; Shiraishi K; Kua LF; Koh V; Ohmori M; Kimura A; Inoue S; Okayama H; Suzuki Y; Nakazawa T; Ichikawa D; Kono K
Int J Oncol; 2019 Jun; 54(6):2030-2038. PubMed ID: 31081058
[TBL] [Abstract][Full Text] [Related]
19. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.
Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
Mol Diagn Ther; 2015 Apr; 19(2):91-7. PubMed ID: 25758902
[TBL] [Abstract][Full Text] [Related]
20. Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary.
Rassy E; Boussios S; Pavlidis N
Eur J Clin Invest; 2021 Sep; 51(9):e13583. PubMed ID: 33970501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
